USA – Toragen, a San Diego, CA-based biotechnology company targeting the root cause of virally induced cancers, raised $5.4M in Seed funding.
The round was led by Mr. Paul Engler.The company intends to use the funds to conduct its Phase I clinical trial with the lead drug candidate, to advance pre-clinical work on its compounds, for payroll for the research, development and management teams as well as general corporate overhead.Founded by Andrew Sharabi, MD, PhD, Associate Professor of Radiation Medicine and Applied Sciences at UC San Diego, and led by CEO Sandra Coufal, Toragen is a biotechnology company that focuses on developing, repurposing and commercializing drugs targeting cancers caused by the human papillomavirus (“HPV”).01/10/2022
